NO973875L - Fremgangsmåte for stimulering av en immunrespons - Google Patents

Fremgangsmåte for stimulering av en immunrespons

Info

Publication number
NO973875L
NO973875L NO973875A NO973875A NO973875L NO 973875 L NO973875 L NO 973875L NO 973875 A NO973875 A NO 973875A NO 973875 A NO973875 A NO 973875A NO 973875 L NO973875 L NO 973875L
Authority
NO
Norway
Prior art keywords
immune response
stimulating
individuals
pathogenic
ligand
Prior art date
Application number
NO973875A
Other languages
English (en)
Norwegian (no)
Other versions
NO973875D0 (no
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO973875D0 publication Critical patent/NO973875D0/no
Publication of NO973875L publication Critical patent/NO973875L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
NO973875A 1995-03-01 1997-08-22 Fremgangsmåte for stimulering av en immunrespons NO973875L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (2)

Publication Number Publication Date
NO973875D0 NO973875D0 (no) 1997-08-22
NO973875L true NO973875L (no) 1997-10-31

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973875A NO973875L (no) 1995-03-01 1997-08-22 Fremgangsmåte for stimulering av en immunrespons

Country Status (15)

Country Link
EP (1) EP0812206B1 (ko)
JP (1) JP3657271B2 (ko)
KR (1) KR19980702490A (ko)
AT (1) ATE220331T1 (ko)
AU (1) AU699291B2 (ko)
CA (1) CA2213798C (ko)
DE (1) DE69622259T2 (ko)
DK (1) DK0812206T3 (ko)
ES (1) ES2179187T3 (ko)
FI (1) FI973484A (ko)
MX (1) MX9706588A (ko)
NO (1) NO973875L (ko)
NZ (1) NZ305083A (ko)
PT (1) PT812206E (ko)
WO (1) WO1996026735A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
CA2313805A1 (en) * 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
DE69941165D1 (de) * 1998-05-23 2009-09-03 Univ Leiden Medical Ct CD40 bindende Moleküle und CTL Peptide zur Behandlung von Tumoren
EP1255560B1 (en) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40 ligand adjuvant for respiratory syncytial virus vaccine
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PL2214701T3 (pl) 2007-11-01 2017-01-31 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
KR102007132B1 (ko) 2010-06-09 2019-08-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (en) 2013-03-15 2016-11-09 Univ Arkansas COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0822199T3 (da) * 1991-10-25 2004-12-27 Amgen Inc N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
DK0724456T3 (da) * 1993-10-01 2004-04-13 Immunex Corp CD40-Antistoffer

Also Published As

Publication number Publication date
PT812206E (pt) 2002-11-29
DE69622259T2 (de) 2003-03-27
AU699291B2 (en) 1998-11-26
ES2179187T3 (es) 2003-01-16
DK0812206T3 (da) 2002-09-09
ATE220331T1 (de) 2002-07-15
JPH11506418A (ja) 1999-06-08
KR19980702490A (ko) 1998-07-15
EP0812206A1 (en) 1997-12-17
CA2213798C (en) 2001-02-06
JP3657271B2 (ja) 2005-06-08
WO1996026735A1 (en) 1996-09-06
EP0812206B1 (en) 2002-07-10
AU5301196A (en) 1996-09-18
DE69622259D1 (de) 2002-08-14
FI973484A0 (fi) 1997-08-25
MX9706588A (es) 1997-11-29
FI973484A (fi) 1997-10-24
NO973875D0 (no) 1997-08-22
NZ305083A (en) 1999-06-29
CA2213798A1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DK0724456T3 (da) CD40-Antistoffer
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
ATE163195T1 (de) Lösliche liganden für cd40
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers